Catalyst

Slingshot members are tracking this event:

Phase 1b study assessing AFM13/KEYTRUDA combo in lymphoma to be initiated in the first half of 2016

Source Link:
http://www.affimed.com/pdf/160125_afmd_merck_release_final.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRK
100%
AFMD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "initiated multiple new clinical trials for AFM11 and AFM13, including our combination therapy with Keytruda"
http://www.affimed.c...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 10, 2016
Occurred Source:
http://www.affimed.com/pdf/20160810_affimed_pr_2q16_final.pdf
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Lymphoma, Afm13, Keytruda, Combo, Phase 1b Initiation, Clinical Research Collaboration
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.